Key facts
- It has raised $29.4M; the latest was Early Stage VC in Dec 2025.
- Notable investors include HSG (Hong Kong), Shenzhen Yifeng Investment Management Enterprise, Hangzhou Capital, Holley Group, Jingjie Investment — 11 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 11 names
- ·Watchlist + deal alerts for LingyiMed
- ·The full record, as it builds
Funding rounds
No funding rounds for LingyiMed are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About LingyiMed
Developer of biotechnology materials designed for pharmaceutical research and clinical application purposes. The company operates a functional validation platform for rare disease animal models dedicated to innovated source, focusing on metabolic, CNS, ophthalmic, and other genetic rare diseases, enabling effective detection of rare disease in animals.
- Sector
- Healthcare
- HQ
- Hangzhou, China
- Founded
- 2021
- Employees
- 40
- Website
- lingyimed.com/
- Ownership
- Privately Held (backing)
LingyiMed doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in LingyiMed shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on LingyiMed in its N-PORT filings yet. We sweep new filings monthly.